Patient P-02132
Synthetic patientMETA-24 · Day 128 · 45–54 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
79%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient accepted — Started SC-12 in the companion
- Day 78 GI symptom burden −12% vs expected — Supportive Compound SC-12
- Day 81 GI-04 recommended — GI Support Protocol GI-04
- Day 82 Patient accepted — Started GI-04 in the companion
- Day 84 Tolerance state changed — Unstable → Improving
- Day 90 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 69.
Primary contributors, last 14 days
- Inflammatory activity-7
- Toxicity-5
- GI instability+4
- Nutritional resilience+3
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 71Result: symptom burden −12%
- GI Support Protocol GI-04Day 81Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
86%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable35 min
worsening · -6.7 vs previous 14 d
Sleep duration
Wearable6 h
stable · -0.0 vs previous 14 d
Energy level
Daily log2.3/10
worsening · -0.6 vs previous 14 d
Steps
Wearable3,922
worsening · -576 vs previous 14 d
GI burden
Companion64.3/100
stable · +2.2 vs previous 14 d
Adherence
Companion47.1 %
worsening · -11.1 vs previous 14 d
Sleep quality
Wearable24.7/100
worsening · -2.6 vs previous 14 d
Glucose, CGM daily mean
CGM154 mg/dL
stable · -0.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 21 from the failing basin, 69 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 42 similar · onset 3 d · confidence 74%
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 74%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 74%
- More proteinGI -4.3 next day on high-intake days · n 19
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- Keep histamine lowGI +3.1 next day on high-intake days · n 25
- Keep fat lowGI +2.8 next day on high-intake days · n 27
- Keep alcohol lowGI +2.1 next day on high-intake days · n 22
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.3supporter · 95%
- Histamine load+3.1detractor · 95%
- Dietary fat load+2.8detractor · 95%
- Alcohol+2.1detractor · 78%
- Ultra-processed food+1.7no signal · 55%
- Insoluble fibre+1.4no signal · 44%
- Simple carbohydrates-0.7no signal · 17%
- Caffeine-0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 6.0 h, below personal baseline
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 56
- WearableHRV 24 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable3,922 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 36/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 46
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 36/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 22 ms
- Sleep
- 5.9 h
- Steps
- 3,900
- Resting HR
- 84 bpm
Daily log: GI score 64, nutritional resilience 38, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.